FY2026 EPS Estimates for TSE:BHC Lifted by Zacks Research

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research raised their FY2026 earnings estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Tuesday, September 22nd. Zacks Research analyst Team now anticipates that the company will earn $5.95 per share for the year, up from their previous forecast of $5.88. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q1 2027 earnings at $1.18 EPS, Q2 2027 earnings at $1.28 EPS, Q3 2027 earnings at $1.50 EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at $5.40 EPS and Q2 2028 earnings at $1.21 EPS.

Bausch Health Companies (TSE:BHC) last posted its quarterly earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. Bausch Health Companies had a negative net margin of 12.02% and a positive return on equity of 87.57%. The company had revenue of C$4.05 billion for the quarter.

Separately, Jefferies Financial Group raised Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold”.

Bausch Health Companies Stock Down 1.6%

Shares of BHC opened at C$8.04 on Thursday. The company has a 50-day simple moving average of C$8.32 and a 200-day simple moving average of C$7.65. The firm has a market capitalization of C$3.01 billion, a P/E ratio of -2.73, a P/E/G ratio of 0.21 and a beta of 0.71. The company has a debt-to-equity ratio of -1,173.29, a quick ratio of 0.58 and a current ratio of 1.44. Bausch Health Companies has a 52 week low of C$6.10 and a 52 week high of C$11.08.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.